Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
- 66 Downloads
Purpose of Review
The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.
Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph−) ALL in adults and children.
Currently, the only bispecific antibody (bsAb) approved for its use in hematologic malignancies is blinatumomab. However, multiple trials are under development not only to explore blinatumomab’s clinical activity in other neoplasia, such as lymphoma or multiple myeloma, but also to develop new molecules against different antigens.
KeywordsAntibodies Bispecific antibodies Antineoplastic agents Immunotherapy Acute lymphoblastic leukemia T-lymphocytes
Compliance with Ethical Standards
Conflict of Interest
Roberta Demichelis-Gómez has received research funding through grants from Amgen and Novartis; has received speakers’ honoraria from AbbVie, Amgen, Celgene, Novartis, and Shire; has received reimbursement for travel expenses from AbbVie and Amgen; and has received compensation from AbbVie and Novartis for participation on advisory boards.
Daniela Pérez-Sámano declares that she has no conflict of interest.
Christianne Bourlon has received speakers’ honoraria from Shire.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Goebler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele h NR, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–11.CrossRefGoogle Scholar
- 14.Topp MS, GÖkbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of anti-C19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphobastic leukemia. J Clin Oncol. 2014;32(36):4134–40.CrossRefGoogle Scholar
- 16.• Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47 Phase III clinical trial that compared Blinatumomab to standard chemotherapy. Demonstrated that Blinatumomab group achieved higher rates of CR, OS, and RFS. CrossRefGoogle Scholar
- 17.• Von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381–9 Phase I/II clinical trial able to demonstrate the activity of Blinatumomab in the r/r pediatric setting. CrossRefGoogle Scholar
- 18.Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single arm, multicenter study. J Clin Oncol. 2017;35(16):1795–802.CrossRefGoogle Scholar
- 19.Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897–901.CrossRefGoogle Scholar
- 20.Blincyto (blinatumomab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2014. https://www.blincyto.com.
- 26.Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb HJ. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013;11:160.CrossRefGoogle Scholar
- 27.Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, et al. Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. Br J Haematol. 2015;169:90–102.CrossRefGoogle Scholar
- 29.Bannerji R, Advani RH, Brown JR, Arnason JE, Barnes JA, Allan JN, et al. Safety and preliminary clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed antibody therapy. Blood. 2017;130:1550.Google Scholar
- 30.Topp MS, Borchmann P, Wagner-Johnston ND, Provencio M, Cordoba R. Papadopoulos K. Safety and Preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies. Blood. 2017;130:1495.Google Scholar
- 31.Bacac M, Umaña P, Herter S, Colombetti S, Sam J, Le Clech M, et al. CD20 Tcb (RG6026), a novel “2:1” T cell bispecific antibody for the treatment of B cell malignancies. Blood. 2016;129:1836.Google Scholar
- 35.De Zafra C, Balazs M, Fajardo F, Liang L, Zhong W, Henn A, et al. Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody. Blood. 2017;129:500.Google Scholar
- 36.Chu SY, Miranda Y, Phung S, Chen H, Rashid R, Endo NA, et al. Immunotherapy with long-lived anti-CD38 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma. Blood. 2014;124:4727.Google Scholar
- 37.Moore GL, Lee SH, Schubbert S, Miranda Y, Rashid R, Pong E, et al. Tuning T cell affinity improves efficacy and safety of anti-CD38 × anti-CD3 bispecific antibodies in monkeys—a potential therapy for multiple myeloma. Blood. 2015;126:1798.Google Scholar
- 42.Uy GL, Godwin J, Rettig MP, Vey N, Foster M, Arellano ML, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130(Suppl 1):637.Google Scholar
- 43.Rettig MP, Godwin J, Vey N, Fox B, Ballesteros-Merino C, Bifulco CB, et al. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies. Blood. 2017;130(Suppl 1):1365.Google Scholar